Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?

Key Highlights

• AVONELLE-X: In the largest long-term extension trial in neovascular AMD (nAMD), Vabysmo® sustained efficacy, safety and durability for up to 4 years, with ~80% of patients on extended dosing
• SALWEEN: In patients with polypoidal choroidal vasculopathy (PCV), >60% achieved complete resolution of damaging lesions and meaningful vision gains after one year
• Vabysmo confirmed a consistent, well-tolerated safety profile across studies, reinforcing its potential as a durable treatment option for hard-to-treat retinal diseases

Durability Demonstrated in AVONELLE-X
Roche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that nearly 80% of nAMD patients extended their Vabysmo treatment intervals to every three or four months. Vision remained stable and anatomic benefits observed in the pivotal TENAYA and LUCERNE trials were maintained, underscoring Vabysmo’s durability and long-term disease control.

Breakthrough in PCV Treatment with SALWEEN
In the Phase IIIb/IV SALWEEN study across nine Asian markets, patients with PCV — a difficult-to-treat nAMD subtype — gained an average of 8.9 letters in visual acuity at one year. More than 60% had complete resolution of polypoidal lesions, and over 50% extended dosing to every five months. These results highlight Vabysmo’s potential to provide meaningful improvements in a condition disproportionately affecting Asian populations.

Global Reach and Growing Impact
Vabysmo is now approved in over 100 countries for nAMD and diabetic macular edema (DME), and in 60+ countries for macular edema following retinal vein occlusion (RVO). More than 8 million doses have been distributed worldwide since its first U.S. approval in 2022, making it one of the fastest-growing treatments in ophthalmology.

About Roche
Roche, founded in 1896 in Basel, Switzerland, is the world’s largest biotechnology company and a global leader in in-vitro diagnostics. With a strong focus on ophthalmology, oncology, immunology and neuroscience, Roche combines Diagnostics and Pharma with real-world data insights to advance personalised healthcare. For over 125 years, Roche has pursued scientific excellence to improve lives and is committed to achieving net zero emissions by 2045.